Ireland
--:--IST
Latest
Clinical Trials in France / NCT06343844
Recruiting Not applicable

Disparities in Myocardial Infarction Remodeling According to Gender

NCT06343844 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-07-15
Last updated
2026-02-09

Condition(s) studied

Myocardial InfarctionVentricular Remodeling

Investigational drug(s) / intervention(s)

cardiac imaging to assess left ventricular volumes and function

cardiac imaging to assess left ventricular volumes and function: non-invasive cardiac imaging (echocardiography and MRI)

Study summary

Following myocardial infarction, female individuals demonstrate a poorer prognosis, characterized by elevated rates of mortality and heart failure. A primary hypothesis suggests unfavorable cardiac remodeling in women. This remodeling, defined as alterations in cardiac size and shape post-infarction, necessitates repeated non-invasive imaging for study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \> 18 years * First myocardial infarction with ST-segment elevation during the hospital phase * Coronary angiography performed within 72 hours of the infarction * Inclusion in the RIMA registry * Patient affiliated or beneficiary of a social security scheme; Signature of informed consent Exclusion Criteria: * Patients already enrolled in the study * Poor understanding of the French language * Pregnant, breastfeeding, or postpartum women * Individuals deprived of liberty by judicial or administrative decision; Individuals receiving psychiatric care under coercion * Individuals subject to a legal protection measure; Individuals incapable of giving consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital, Angers Angers France Recruiting

More University Hospital, Angers trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06343844 on ClinicalTrials.gov ↗ ← All trials in France